A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.
| dc.contributor.author | Shalini, Anjali | |
| dc.contributor.author | Kaur, Raman Preet | |
| dc.contributor.author | Munshi, Anjana | |
| dc.date.accessioned | 2018-06-08T05:10:11Z | |
| dc.date.accessioned | 2024-08-14T07:41:00Z | |
| dc.date.available | 2018-06-08T05:10:11Z | |
| dc.date.available | 2024-08-14T07:41:00Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | BRCA2is the main susceptibility gene known to be involved in the pathogenesis of breast cancer. It plays an important role in maintaining the genome stability by homologous recombination through DNA double-strand breaks repairing, by interacting with various other proteins including RAD51, DSS1, RPA, MRE11, PALB2, and p53. BRCA2-deficient cells show the abnormalities of chromosome number. BRCA2 is also found to be involved in centrosome duplication specifically in the metaphase to anaphase transition. Inactivation or depletion of BRCA2 leads to centrosome amplification that results in unequal separation of chromosomes. BRCA2 localizes with central spindle and midbody during telophase and cytokinesis. Inactivation or depletion of BRCA2 leads to multinucleation of cell. Around 2000 mutations have been reported in BRCA2 gene. BRCA2-deficient tumors are being taking into consideration for targeted cancer therapy by using different inhibitors like poly ADP-ribose polymerase and thymidylate synthase. The present review focusses on the role of BRCA2 in various critical cellular processes based on the mechanistic approaches. Mutations reported in the BRCA2 gene in various ethnic groups till date have also been compiled with an insight into the functional aspects of these alterations. The therapeutic strategies for targeting BRCA2-deficient tumors have also been targeted. | en_US |
| dc.identifier.citation | Shailani, A., Kaur, R.P. & Munshi, (2018) A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.A. Medical Oncology. 35: 18. https://doi.org/10.1007/s12032-018-1085-8 | en_US |
| dc.identifier.doi | 10.1007/s12032-018-1085-8 | |
| dc.identifier.issn | Print-1357-0560 | |
| dc.identifier.issn | Online- 1559-131X | |
| dc.identifier.uri | http://10.2.3.109/handle/32116/681 | |
| dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12032-018-1085-8 | |
| dc.language.iso | en | en_US |
| dc.publisher | Springer | en_US |
| dc.subject | Breast | en_US |
| dc.subject | Carcinoma | en_US |
| dc.subject | BRCA2 | en_US |
| dc.subject | Homologous recombination | en_US |
| dc.subject | Telophase | en_US |
| dc.title | A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors. | en_US |
| dc.title.journal | Medical Oncology | |
| dc.type | Article | en_US |